PMID- 22917219 OWN - NLM STAT- MEDLINE DCOM- 20130409 LR - 20220311 IS - 1477-7525 (Electronic) IS - 1477-7525 (Linking) VI - 10 DP - 2012 Aug 21 TI - Change in health status (EQ-5D) over 5 years among individuals with and without type 2 diabetes mellitus in the SHIELD longitudinal study. PG - 99 LID - 10.1186/1477-7525-10-99 [doi] AB - BACKGROUND: Health-related quality of life studies among adults with type 2 diabetes mellitus, using the EQ-5D, have been short term and have not assessed change over years. This study assessed the change in health status and health-related quality of life over 5 years among individuals with and without diabetes. METHODS: Respondents to the US Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD) completed the EuroQol-5D (EQ-5D) at baseline (2004) and 5 years later (2009). Visual analog scale (VAS) score and health index score were computed at baseline and year 5, and the change over 5 years was measured for individuals with type 2 diabetes mellitus (T2DM) and those without diabetes, and T2DM adults with and without diabetic complications. Linear regression models were used to determine change in EQ-5D score, controlling for age, gender, race, education, household income, and body mass index (BMI). RESULTS: There was significantly greater decline in the EQ-5D index score in the T2DM group (-0.031 [SD 0.158]), compared with those without diabetes (-0.016 [0.141], p = 0.001). Compared with respondents without diabetes, those with T2DM had a larger reduction in EQ-5D index score, after controlling for demographics (p = 0.001). EQ-5D VAS score declined over 5 years for both groups: -1.42 (18.1) for the T2DM group, and -0.63 (15.8) for the group without diabetes, but the between-group difference was not significant either before (p = 0.09) or after (p = 0.12), controlling for demographics. T2DM respondents with diabetic complications had a greater decline in EQ-5D scores than T2DM respondents without complications (p < 0.05). CONCLUSION: Over a 5-year period, health status of respondents with T2DM declined significantly compared with those with no diabetes, indicating that the burden of the disease has a long-term detrimental impact. This decline in health status is likely to impact utility scores (fewer quality-adjusted life years) for economic evaluations. FAU - Grandy, Susan AU - Grandy S AD - AstraZeneca LP, Wilmington, DE, USA. FAU - Fox, Kathleen M AU - Fox KM CN - SHIELD Study Group LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20120821 PL - England TA - Health Qual Life Outcomes JT - Health and quality of life outcomes JID - 101153626 SB - IM MH - Adult MH - Aged MH - Body Mass Index MH - Cross-Sectional Studies MH - Diabetes Mellitus, Type 1/complications/epidemiology MH - *Diabetes Mellitus, Type 2/complications/epidemiology MH - Diabetic Nephropathies/diagnosis MH - Diabetic Retinopathy/diagnosis MH - Female MH - *Health Knowledge, Attitudes, Practice MH - *Health Status Indicators MH - Humans MH - Longitudinal Studies MH - Male MH - Middle Aged MH - Pain Measurement/statistics & numerical data MH - *Quality of Life MH - Quality-Adjusted Life Years MH - Regression Analysis MH - Risk Factors MH - Socioeconomic Factors MH - *Surveys and Questionnaires MH - United States/epidemiology PMC - PMC3490883 FIR - Bays, Harold IR - Bays H FIR - Bazata, Debbra D IR - Bazata DD FIR - Gavin, James R 3rd IR - Gavin JR 3rd FIR - Green, Andrew J IR - Green AJ FIR - Lewis, Sandra J IR - Lewis SJ FIR - Reed, Michael L IR - Reed ML FIR - Rodbard, Helena W IR - Rodbard HW EDAT- 2012/08/25 06:00 MHDA- 2013/04/10 06:00 PMCR- 2012/08/21 CRDT- 2012/08/25 06:00 PHST- 2012/06/01 00:00 [received] PHST- 2012/08/16 00:00 [accepted] PHST- 2012/08/25 06:00 [entrez] PHST- 2012/08/25 06:00 [pubmed] PHST- 2013/04/10 06:00 [medline] PHST- 2012/08/21 00:00 [pmc-release] AID - 1477-7525-10-99 [pii] AID - 10.1186/1477-7525-10-99 [doi] PST - epublish SO - Health Qual Life Outcomes. 2012 Aug 21;10:99. doi: 10.1186/1477-7525-10-99.